dLocal Ltd reported strong financial results for the first quarter of 2025, surpassing analyst expectations. The Uruguay-based payment platform posted revenue of $216.8 million, marking an 18% year-over-year increase. Adjusted earnings per share (EPS) came in at $0.15, exceeding the consensus estimate of $0.12. Total payment volume (TPV) reached $8.1 billion, reflecting a 53% year-over-year growth and a 5% increase quarter-over-quarter. Gross profit rose by 35% to $84.9 million, while adjusted EBITDA increased 57% to $57.9 million, with a margin of 27%. The company attributed its strong performance to geographic diversification and growth outside its core markets. Following the earnings release, dLocal's shares rose by 13% in after-hours trading and were up 24.6% in pre-market trading. In contrast, Globant SA and Travere Therapeutics experienced notable stock declines after their respective earnings reports and regulatory updates. Globant reported a first-quarter 2025 revenue of $611.1 million and adjusted EPS of $1.50 but faced a nearly 30% pre-market share drop amid challenging macroeconomic conditions and lowered price targets by major brokers. Travere Therapeutics' shares fell over 17% pre-market after the FDA accepted a supplemental new drug application for FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS) and scheduled an advisory committee meeting, with no priority review granted and retail investors showing limited concern.